Research programme: anti-infectives - Novozymes A/S

Drug Profile

Research programme: anti-infectives - Novozymes A/S

Alternative Names: Eurocin; Munumbicin A; Munumbicin B; Munumbicin D; Munumbicins - Novozymes; Novicidin; Novispirin; Novispirins series - Novozymes; NZ 1000 series - Novozymes; NZ 1001; NZ 2000 series - Novozymes; Plectasin; Plectasins series - Novozymes; Streptomycins - Novozymes

Latest Information Update: 17 Aug 2012

Price : $50

At a glance

  • Originator Novozymes A/S
  • Class Peptides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Gram-negative infections; Gram-positive infections

Highest Development Phases

  • Discontinued Gram-negative infections; Gram-positive infections

Most Recent Events

  • 27 Oct 2011 Discontinued - Preclinical for Gram-positive infections in Denmark (unspecified route)
  • 27 Oct 2011 Discontinued - Preclinical for Gram-negative infections in Denmark (unspecified route)
  • 27 Oct 2011 Research programme: anti-infectives - Novozymes A/S is available for licensing as of 27 Oct 2011. http://www.novozymes.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top